263
Views
17
CrossRef citations to date
0
Altmetric
Original Research

Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis

, , , , &
Pages 632-641 | Received 03 Jan 2018, Accepted 26 Feb 2018, Published online: 20 Mar 2018

References

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61(2):69–90. PMID:21296855.
  • El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76. doi:10.1053/j.gastro.2007.04.061. PMID:17570226.
  • De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 2014;15(1):23–34. doi:10.1016/S1470-2045(13)70546-1. PMID:24314615.
  • Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World Journal Of Hepatol. 2015;7(12):1708–17. doi:10.4254/wjh.v7.i12.1708.
  • Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma–an updated analysis of randomized controlled trials. Alimentary Pharmacol Therapeutics. 2006;23(11):1535–47. doi:10.1111/j.1365-2036.2006.02932.x.
  • Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. World J Hepatol. 2015;7(10):1355–68. doi:10.4254/wjh.v7.i10.1355. PMID:26052381.
  • Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation. 2005;79(7):855–7. doi:10.1097/01.TP.0000154913.88193.FF. PMID:15818333.
  • Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248(5):857–62. doi:10.1097/SLA.0b013e3181896278. PMID:18948815.
  • Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530–4. doi:10.1038/17401. PMID:10028970.
  • Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128–35. doi:10.1038/nm0202-128. PMID:11821896.
  • Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31(5):335–40. doi:10.1016/S0009-9120(98)00045-9. PMID:9721431.
  • Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, et al. Clinical development of mTor inhibitors for renal cancer. Expert Opin Invest Drugs. 2017;26(11):1229–37. doi:10.1080/13543784.2017.1384813.
  • Hayashi T, Yamashita T, Okada H, Oishi N, Sunagozaka H, Nio K, et al. A novel mTOR inhibitor; Anthracimycin for the treatment of human hepatocellular carcinoma. Anticancer Res. 2017;37(7):3397–403. PMID:28668827.
  • Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg. 1999;230(3):441–8; discussion 8–9. doi:10.1097/00000658-199909000-00016. PMID:10493490.
  • Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol. 2005;11(10):1420–5. doi:10.3748/wjg.v11.i10.1420. PMID:15770715.
  • Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan Criteria. Transplantation Proc. 2008;40(10):3548–53. doi:10.1016/j.transproceed.2008.03.165.
  • Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transplantation. 2008;14(5):633–8. doi:10.1002/lt.21420. PMID:18324656.
  • Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transplantation. 2009;15(12):1834–42. doi:10.1002/lt.21953. PMID:19938137.
  • Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatol (Baltimore, Md). 2010;51(4):1237–43. doi:10.1002/hep.23437.
  • Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation. 2010;89(2):227–31. doi:10.1097/TP.0b013e3181c3c540. PMID:20098287.
  • Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012;18(1):62–9. doi:10.1002/lt.22441. PMID:21964956.
  • Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Alimentary Pharmacol Therapeutics. 2013;37(4):411–9. doi:10.1111/apt.12185.
  • Geissler EK, Schnitzbauer AA, Zölke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with Hepatocellular carcinoma: A randomized, Multicenter, open-label phase 3 Trial. Transplantation. 2016;100(1):116–25. doi:10.1097/TP.0000000000000965. PMID:26555945.
  • Xu SL, Zhang YC, Wang GY, Yang Q, Liu B, Zhang J, et al. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2016;40(6):674–81. doi:10.1016/j.clinre.2016.03.006. PMID:27825633.
  • Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi:10.1007/s10654-010-9491-z. PMID:20652370.
  • Dayan N, Filion KB, Okano M, Kilmartin C, Reinblatt S, Landry T, et al. Cardiovascular risk following fertility therapy: Systematic review and meta-analysis. J Am College Cardiol. 2017;70(10):1203–13. doi:10.1016/j.jacc.2017.07.753.
  • Feng L, Ni Z, Song S, Lin F, Fu H, Wang Z, et al. Effect of conversion to sirolimus-based immunosuppression on tumor recurrence after liver transplantation for hepatocellular carcinoma beyond the Standard Milan Criteria. Acad J Second Military Medical University. 2012;33(6):642–5.
  • Zhao X, Wang M, Wu J, Lin D, Guo Q, Lai W, et al. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation]. Zhonghua Wai Ke Za Zhi [Chinese J Surg]. 2014;52(4):245–8.
  • Shen C, Peng C, Shen B, Zhu Z, Xu N, Li T, et al. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation. Oncotarget. 2016;7(38):62647–56. doi:10.18632/oncotarget.11591. PMID:27577068.
  • Yanik EL, Chinnakotla S, Gustafson SK, Snyder JJ, Israni AK, Segev DL, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transplantation. 2016;22(5):627–34. doi:10.1002/lt.24395. PMID:26784951.
  • Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9. doi:10.1056/NEJM199603143341104. PMID:8594428.
  • Vibert E, Duclos-Vallee JC, Ghigna MR, Hoti E, Salloum C, Guettier C, et al. Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology (Baltimore, Md). 2011;53(2):475–82. doi:10.1002/hep.24062. PMID:21274869.
  • Cholongitas E, Mamou C, Rodriguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transplant Int. 2014;27(10):1039–49. doi:10.1111/tri.12372.
  • Decaens T, Luciani A, Itti E, Hulin A, Roudot-Thoraval F, Laurent A, et al. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis. 2012;44(7):610–6. doi:10.1016/j.dld.2012.02.005. PMID:22459565.
  • Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–66. doi:10.1111/liv.12818. PMID:25752327.
  • Alamo JM, Barrera L, Casado MD, Bernal C, Marin LM, Suarez G, et al. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. Transplantation Proc. 2009;41(6):2181–3. doi:10.1016/j.transproceed.2009.06.083.
  • Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol (Northwood, London, England). 2010;27(2):255–61. doi:10.1007/s12032-009-9201-4.
  • Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Cur Opin Pharmacol. 2008;8(4):393–412. doi:10.1016/j.coph.2008.08.004.
  • Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93.. doi:10.1016/j.cell.2012.03.017. PMID:22500797.
  • Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer. 2012;11:85. doi:10.1186/1476-4598-11-85. PMID:23167739.
  • Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17(15):1829–34. doi:10.1101/gad.1110003. PMID:12869586.
  • Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99(21):13571–6. doi:10.1073/pnas.202476899. PMID:12271141.
  • Facciorusso A, Licinio R, Carr BI, Di Leo A, Barone M. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. Exp Rev Gastroenterol Hepatol. 2015;9(7):993–1003. doi:10.1586/17474124.2015.1040763.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.